Kidney Transplant Patients Identified at High Risk of Rejection
|
By LabMedica International staff writers Posted on 18 Nov 2014 |
|
A quantitative real-time PCR (qPCR)-based assay can identify kidney transplant patients who are at high risk of acute rejection.
Minnie Sarwal at the University of California (San Francisco, CA, USA) and colleagues examined gene expression data from more than 430 renal transplant patients and developed a 17-gene set that could distinguish patients at high risk of rejection. They also developed an algorithm to classify patients into high- or low-risk categories using a numerical risk score.
Called kSORT for Kidney Solid Organ Response Test, the assay has the potential to become a simple, robust, and clinically applicable blood test, the scientists stated in their November 2014 PLOS Medicine paper.
In the US, there are some 17,000 kidney transplants a year, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the researchers noted that acute rejection occurs in some 15%–20% of patients even with immunosuppressive therapy. Currently, clinicians monitor creatinine levels as a marker for rejection, followed by a biopsy to confirm rejection. The new assay has a less invasive approach, and can identify rejection events early on.
A further seven genes were added to optimize the panel for both an adult and pediatric population. The 17 genes could predict 39 of 47 AR samples correctly as AR and 87 of 96 non-AR samples as non-AR, a sensitivity of nearly 83% and a specificity of just over 90%.
To develop the test, 558 blood samples from 436 adult and pediatric renal transplant patients in the US, Mexico, and Spain were collected. Using a set of 143 adult samples, the researchers found 31 genes that were differentially expressed between adult acute rejection (AR) and non-AR patients, as determined through kidney biopsies. A subset of 15 genes was able to classify nearly 92% of the AR and non-AR adult samples, but not in pediatric cases.
Related Links:
University of California
Minnie Sarwal at the University of California (San Francisco, CA, USA) and colleagues examined gene expression data from more than 430 renal transplant patients and developed a 17-gene set that could distinguish patients at high risk of rejection. They also developed an algorithm to classify patients into high- or low-risk categories using a numerical risk score.
Called kSORT for Kidney Solid Organ Response Test, the assay has the potential to become a simple, robust, and clinically applicable blood test, the scientists stated in their November 2014 PLOS Medicine paper.
In the US, there are some 17,000 kidney transplants a year, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the researchers noted that acute rejection occurs in some 15%–20% of patients even with immunosuppressive therapy. Currently, clinicians monitor creatinine levels as a marker for rejection, followed by a biopsy to confirm rejection. The new assay has a less invasive approach, and can identify rejection events early on.
A further seven genes were added to optimize the panel for both an adult and pediatric population. The 17 genes could predict 39 of 47 AR samples correctly as AR and 87 of 96 non-AR samples as non-AR, a sensitivity of nearly 83% and a specificity of just over 90%.
To develop the test, 558 blood samples from 436 adult and pediatric renal transplant patients in the US, Mexico, and Spain were collected. Using a set of 143 adult samples, the researchers found 31 genes that were differentially expressed between adult acute rejection (AR) and non-AR patients, as determined through kidney biopsies. A subset of 15 genes was able to classify nearly 92% of the AR and non-AR adult samples, but not in pediatric cases.
Related Links:
University of California
Gold Member
Aspiration System
VACUSAFE
Multi-Chamber Washer-Disinfector
WD 390
Automated Urinalysis Solution
UN-9000
Latest Molecular Diagnostics News
- Interpretable AI Tool Improves Prediction of Immunotherapy Response
- Blood Test Using Circular RNA Biomarkers Predicts Alzheimer’s Progression
- At-Home PCR Test Detects Flu and COVID-19 in 30 Minutes
- New Sequencing Platform Delivers Same-Day Whole-Genome Results
- Blood-Based RNA Biomarker Improves Prediction of Alzheimer’s Onset
- New Molecular Marker Helps Predict Multiple Myeloma Prognosis
- Gene Expression Test Supports Metastatic Risk Assessment in Melanoma
- Multiplex PCR Test Identifies Seven STI Pathogens in One Hour
- CSF Sequencing Test Aligns with Updated Brain Tumor Guidelines
- Framework Outlines Genomic Testing Strategy for Safer Drug Dosing in Africa
- Point-of-Care PCR Panel Delivers Vaginitis Results in 20 Minutes
- Blood Test Reveals Hidden Pancreatic Cancer After Treatment
- Gene Expression Test Refines Melanoma Biopsy Decision-Making
- Genomic Assays Predict Anthracycline Benefit in Early-Stage Breast Cancer
- Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
- Model Predicts Increased ALS Clinic Visits with Expanded Genetic Testing
Channels
Clinical Chemistry
view channel
ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
Laboratory medicine increasingly intersects with gender-affirming care, where hormone therapy and rigid health record fields can complicate the interpretation of routine tests. Without appropriate clinical... Read more
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Molecular Diagnostics
view channel
Blood Test Using Circular RNA Biomarkers Predicts Alzheimer’s Progression
Alzheimer’s disease evaluation commonly relies on plasma phosphorylated tau 217, along with invasive cerebrospinal fluid (CSF) testing and expensive PET. Blood-based approaches that can stratify risk years... Read more
Interpretable AI Tool Improves Prediction of Immunotherapy Response
Immune checkpoint inhibitors are standard treatment options across many cancers, but only a subset of patients benefit, making patient selection difficult. Because predictive biomarkers remain limited,... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read more
Microbiology
view channel
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read more
Pathology
view channel
AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
Immunotherapy has transformed care for select malignancies, yet predicting which patients with rare cancers are most likely to benefit remains challenging. Clinicians often have only limited biomarkers... Read more
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Industry
view channel
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more
